Non-Muscle Invasive Bladder Carcinoma Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Non-Muscle Invasive Bladder Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 4

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Carcinoma
Ohio State University Comprehensive Cancer Center40 enrolled1 locationNCT07474519
Recruiting
Phase 1

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8+1 more
University of California, Davis12 enrolled1 locationNCT06173349
Recruiting
Phase 3

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Stage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8Recurrent Non-Muscle Invasive Bladder Carcinoma
Alliance for Clinical Trials in Oncology330 enrolled55 locationsNCT07000084
Recruiting
Phase 2

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Recurrent Bladder CarcinomaNon-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
Roswell Park Cancer Institute344 enrolled1 locationNCT06733363
Recruiting
Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Urothelial Carcinoma BladderNon Muscle Invasive Bladder CancerNMIBC+4 more
Aura Biosciences55 enrolled17 locationsNCT05483868
Recruiting
Phase 1Phase 2

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
Mayo Clinic40 enrolled1 locationNCT06704191